Mr Mfazo Hove, ZEISS Key Opinion Leader, at European Cataract & Corneal User Meeting 2025 has highlighted Blue Fin Vision for surgeon-led innovation and patient-centric care. London, UK, October 1, 2025 — Blue Fin Vision,… Read More »Blue Fin Vision Showcased at ZEISS European Cataract & Corneal User Meeting 2025
California, United States, October 1, 2025 — JetRuby Agency, an international software development company with more than a decade of experience delivering digital products, today announced the relaunch of its corporate website, jetruby.com. The redesigned… Read More »JetRuby Launches New Website Featuring Improved Performance and Global Case Studies
The change to West Yorkshire Electrical’s approach now means that the firm can now schedule more than 70 new phone calls every month, converting website form enquiries into real calendar appointments. United Kingdom, October 1,… Read More »West Yorkshire Electrical Achieves Over 90% Conversion Rate by Using AI to Book Customer Calls
If you’re looking to make your holiday decor truly stand out, I recommend checking out some of the best outdoor Christmas light projectors. These models deliver vibrant, colorful effects like snowflakes, stars, and festive patterns… Read More »15 Best Outdoor Christmas Light Projectors to Brighten Up Your Holiday Decorations
Looking for the best motorcycle jackets that blend style and safety in 2025? I recommend checking out options like the durable BORLENI full-body gear with CE armor, the versatile Milwaukee Leather hoodie, and the adventure-ready… Read More »15 Best Motorcycle Jackets That Combine Style and Safety in 2025
CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment… Read More »NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board